SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

[1]  Lisa E. Gralinski,et al.  A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures , 2020, Nature.

[2]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[3]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[4]  Shrutika Mintri,et al.  Impact of mRNA chemistry and manufacturing process on innate immune activation , 2020, Science Advances.

[5]  J. Mudgal,et al.  COVID-19: Emergence, Spread, Possible Treatments, and Global Burden , 2020, Frontiers in Public Health.

[6]  Lisa E. Gralinski,et al.  SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.

[7]  M. Fay,et al.  Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling , 2020, medRxiv.

[8]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[9]  Lisa E. Gralinski,et al.  A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures , 2020, bioRxiv.

[10]  B. Graham,et al.  Prototype pathogen approach for pandemic preparedness: world on fire. , 2020, The Journal of clinical investigation.

[11]  B. Graham,et al.  Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance , 2020, bioRxiv.

[12]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[13]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[14]  J. Mascola,et al.  A proof of concept for structure-based vaccine design targeting RSV in humans , 2019, Science.

[15]  M. Moore,et al.  mRNA structure regulates protein expression through changes in functional half-life , 2019, Proceedings of the National Academy of Sciences.

[16]  Kimberly J. Hassett,et al.  Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines , 2019, Molecular therapy. Nucleic acids.

[17]  Jason S McLellan,et al.  Structure-Based Vaccine Antigen Design. , 2019, Annual review of medicine.

[18]  John R Mascola,et al.  Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. , 2018, JAMA.

[19]  Kimberly J. Hassett,et al.  Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. , 2018, Vaccine.

[20]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[21]  N. Sullivan,et al.  Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic , 2017, Nature Immunology.

[22]  R. Baric,et al.  Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease , 2017, Virology.

[23]  U. Şahin,et al.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[25]  Kimberly J. Hassett,et al.  Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  B. Graham,et al.  Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors , 2016, Science Immunology.

[27]  R. Baric,et al.  A mouse model for MERS coronavirus-induced acute respiratory distress syndrome , 2016, Nature Microbiology.

[28]  J. Mascola,et al.  Rapid development of a DNA vaccine for Zika virus , 2016, Science.

[29]  Lisa E. Gralinski,et al.  SARS-like WIV1-CoV poised for human emergence , 2016, Proceedings of the National Academy of Sciences.

[30]  Barney S. Graham,et al.  Pre-fusion structure of a human coronavirus spike protein , 2016, Nature.

[31]  F. Dimaio,et al.  Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer , 2016, Nature.

[32]  Lisa E. Gralinski,et al.  A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.

[33]  Ulas Bagci,et al.  Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.

[34]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[35]  Vineet D. Menachery,et al.  Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus , 2013, Proceedings of the National Academy of Sciences.

[36]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[37]  Lisa E. Gralinski,et al.  A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.

[38]  M. Whitt.  Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. , 2010, Journal of Virological Methods.

[39]  R. Johnston,et al.  Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants , 2006, PLoS medicine.

[40]  H. Klenk,et al.  Proteolytic Activation of Influenza Viruses by Serine Proteases TMPRSS2 and HAT from Human Airway Epithelium , 2006, Journal of Virology.

[41]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[42]  Jingxin Cao,et al.  Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets , 2005, Vaccine.

[43]  Steve Bunk,et al.  World on Fire , 2004, PLoS biology.

[44]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.

[45]  V. Fulginiti,et al.  Altered Reactivity to Measles Virus: Atypical Measles in Children Previously Immunized With Inactivated Measles Virus Vaccines , 1967 .

[46]  F. Sorgel.  Covid-19 Vaccine Development , 2020 .

[47]  M. Osterholm,et al.  Preparing for the next pandemic. , 2005, The New England journal of medicine.

[48]  V. Fulginiti,et al.  Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. , 1967, JAMA.